Citius Pharmaceuticals, Inc. (CTXR)
CTXR Stock Price Chart
Explore Citius Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze CTXR price movements and trends.
CTXR Company Profile
Discover essential business fundamentals and corporate details for Citius Pharmaceuticals, Inc. (CTXR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Oct 2014
Employees
23.00
Website
https://www.citiuspharma.comCEO
Leonard L. Mazur
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
CTXR Financial Timeline
Browse a chronological timeline of Citius Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 12 Feb 2026
Earnings released on 12 Aug 2025
EPS came in at -$0.80 falling short of the estimated -$0.24 by -233.33%.
Earnings released on 14 May 2025
EPS came in at -$1.27 falling short of the estimated -$1.08 by -17.59%.
Earnings released on 14 Feb 2025
EPS came in at -$1.30 falling short of the estimated -$1.25 by -4.00%.
Earnings released on 3 Jan 2025
EPS came in at -$1.75 falling short of the estimated -$0.04 by -4.28K%, while revenue for the quarter reached $155.93K , missing expectations by -97.79%.
Earnings released on 12 Aug 2024
EPS came in at -$1.50 falling short of the estimated -$1.25 by -20.00%.
Earnings released on 14 May 2024
EPS came in at -$1.25 surpassing the estimated -$1.50 by +16.67%.
Earnings released on 14 Feb 2024
EPS came in at -$1.50 falling short of the estimated $3.25 by -146.15%.
Earnings released on 29 Dec 2023
EPS came in at -$1.75 falling short of the estimated -$0.44 by -300.00%.
Earnings released on 14 Aug 2023
EPS came in at -$1.50 matching the estimated -$1.50.
Earnings released on 12 May 2023
EPS came in at -$1.75 falling short of the estimated -$1.00 by -75.00%.
Earnings released on 10 Feb 2023
EPS came in at -$1.00 .
Earnings released on 22 Dec 2022
EPS came in at -$1.25 falling short of the estimated -$1.00 by -25.00%.
Earnings released on 11 Aug 2022
EPS came in at -$1.50 falling short of the estimated -$1.25 by -20.00%.
Earnings released on 12 May 2022
EPS came in at -$1.25 surpassing the estimated -$2.00 by +37.50%.
Earnings released on 10 Feb 2022
EPS came in at -$1.50 matching the estimated -$1.50.
Earnings released on 15 Dec 2021
EPS came in at -$0.75 matching the estimated -$0.75.
Earnings released on 12 Aug 2021
EPS came in at -$1.25 matching the estimated -$1.25.
Earnings released on 13 May 2021
EPS came in at -$1.00 surpassing the estimated -$2.00 by +50.00%.
Earnings released on 11 Feb 2021
EPS came in at -$0.15 falling short of the estimated $0.16 by -193.75%.
Earnings released on 16 Dec 2020
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%.
CTXR Stock Performance
Access detailed CTXR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.